Mylan NV (MYL):医療機器:M&Aディール及び事業提携情報

◆英語タイトル:Mylan NV (MYL) - Medical Equipment - Deals and Alliances Profile
◆商品コード:DATA904C7176
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:66
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥34,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥69,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥103,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mylan NV (Mylan) is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generics and branded medicines, and consumer healthcare products. It offers pharmaceutical products in multiple forms for various disease conditions related to respiratory and allergy, cardiovascular, dermatology, central nervous system (CNS) and cancer, besides anti-rretrovirals, anaphylaxis products and others. The company also offers active pharmaceutical ingredients (APIs). The company sells its products to retail pharmacy chains, wholesalers and distributors, group purchasing organizations, drug store chains, independent pharmacies, drug manufacturers, institutions, and public and governmental agencies. The company markets its products in various countries worldwide. Mylan is headquartered in Hatfield, Hertfordshire, the UK.

Mylan NV (MYL) – Medical Equipment – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Mylan NV, Medical Equipment, Deal Details 11
Venture Financing 11
Zyomyx Raises US$6 Million In First Closing Of Series 2 Preferred Financing 11
Partnerships 12
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Debt Offering 18
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Acquisition 25
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV – Key Competitors 27
Mylan NV – Key Employees 28
Mylan NV – Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Recent Developments 36
Strategy And Business Planning 36
Sep 25, 2018: Mylan signs HIV test commercialisation deal with Atomo Diagnostics 36
Financial Announcements 37
Aug 08, 2018: Mylan reports second quarter 2018 results and updates 2018 guidance 37
May 09, 2018: Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance 42
Feb 28, 2018: Mylan Reports Full Year and Fourth Quarter 2017 Results and Provides 2018 Guidance 44
Nov 06, 2017: Mylan Reports Third Quarter 2017 Results and Updates 2017 Guidance 46
Aug 09, 2017: Mylan Reports Second Quarter 2017 Results and Updates 2017 Guidance 48
May 10, 2017: Mylan Reports First Quarter 2017 Results 52
Mar 01, 2017: Mylan Reports Fourth Quarter and Full Year 2016 Results and Provides 2017 Guidance 54
Corporate Communications 56
May 14, 2018: Mylan and West Virginia University Join Forces to Inspire West Virginia Youth Through STEM-CARE 56
Feb 26, 2018: 16-Year Veteran Director Wendy Cameron to Retire from Mylan Board after 2018 AGM 58
Sep 13, 2017: Mylan Names Dennis Zeleny as Chief Human Relations Officer 59
May 01, 2017: Mylan Nominates Sjoerd Vollebregt for Election to Board of Directors 60
Mar 28, 2017: Mylan Names Former SEC Commissioner Daniel Gallagher as Chief Legal Officer 61
Legal and Regulatory 62
Jun 28, 2018: Mylan Statement: Morgantown Operations 62
Nov 10, 2017: Mylan Announces Voluntary Delisting from the Tel Aviv Stock Exchange 63
Oct 31, 2017: Mylan Provides Statement in Response to Announcement of Proposed Amendments to Civil Complaint 64
Product News 65
Apr 11, 2018: Investor Day Highlights Durability of Mylan’s Global Platform 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Mylan NV, Medical Equipment, Key Facts, 2017 2
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment Deals By Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Deals By Market, 2012 to YTD 2018 9
Mylan NV, Medical Equipment, Deals Summary, 2012 to YTD 2018 10
Zyomyx Raises US$6 Million In First Closing Of Series 2 Preferred Financing 11
Mylan Teoranta Enters into Licensing Agreement with Contura 12
Mylan Enters into Partnership with Atomo Diagnostics 13
Mylan Enters Into Distribution Agreement With Zyomyx For CD4 T-Cell Count Test 14
Phosphagenics Enters Into Licensing Agreement With Agila Specialties For TPM Technology 16
Mylan Specialty Enters Into Licensing Agreement With Pfizer For EpiPen 17
Mylan Prices Private Placement of 5.2% Notes Due 2048 for USD750 Million 18
Mylan Prices Private Placement of 4.55% Notes Due 2028 for USD750 Million 19
Mylan Raises USD551.6 Million in Public Offering of Bonds Due 2020 20
Mylan Raises USD1 Billion in Private Placement of 5.25% Notes Due 2046 21
Mylan Raises USD2.25 Billion in Private Placement of 3.95% Notes Due 2026 22
Mylan Raises USD1 Billion in Private Placement of 2.5% Notes Due 2019 23
Mylan Raises USD2.25 Billion in Private Placement of 3.15% Notes Due 2021 24
Mylan Acquires Meda for USD9.42 Billion 25
Mylan NV, Key Competitors 27
Mylan NV, Key Employees 28
Mylan NV, Other Locations 29
Mylan NV, Subsidiaries 30

List of Figures
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Market, 2012 to YTD 2018 2
Mylan NV, Medical Equipment, Deals By Year, 2012 to YTD 2018 6
Mylan NV, Medical Equipment, Deals by Type, 2012 to YTD 2018 7
Mylan NV, Medical Equipment, Deals By Region, 2012 to YTD 2018 8
Mylan NV, Medical Equipment, Deals by Market, 2012 to YTD 2018 9

★海外企業調査レポート[Mylan NV (MYL):医療機器:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Infratil Ltd (IFT):企業の財務・戦略的SWOT分析
    Infratil Ltd (IFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Solvay Group:企業の戦略・SWOT・財務情報
    Solvay Group - Strategy, SWOT and Corporate Finance Report Summary Solvay Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • ACWA Power International:電力:M&Aディール及び事業提携情報
    Summary ACWA Power International (ACWA Power), a subsidiary of ACWA Holding is a power generation company that develops and operates power generation and desalinated water production plants. The company holds a generation portfolio of power and desalinated water. Its projects comprise in selecting i …
  • Sino Biopharmaceutical Ltd (1177):企業の財務・戦略的SWOT分析
    Sino Biopharmaceutical Ltd (1177) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Tredegar Corp (TG):企業の財務・戦略的SWOT分析
    Tredegar Corp (TG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Circassia Pharmaceuticals Plc (CIR):製薬・医療:M&Aディール及び事業提携情報
    Summary Circassia Pharmaceuticals plc (Circassia) develops and manufactures drugs for the treatment of allergy and respiratory diseases such as asthma. The company’s marketed products include Niox used to assist asthma management and Tudorza for the treatment of chronic obstructive pulmonary disease …
  • Plastopil Hazorea Company Ltd:企業の戦略・SWOT・財務情報
    Plastopil Hazorea Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Plastopil Hazorea Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Second Sight Medical Products Inc (EYES):企業の財務・戦略的SWOT分析
    Summary Second Sight Medical Products Inc (Second Sight) is a medical device company. It develops, manufactures and markets implantable visual prosthetics for blind individuals. The company offers Argus II retinal prosthesis system, a device that restores some functional vision for people suffering …
  • JA Solar Holdings Co Ltd (JASO):企業の財務・戦略的SWOT分析
    JA Solar Holdings Co Ltd (JASO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Tragara Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Tragara Pharmaceuticals Inc (Tragara Pharmaceuticals) is a pharmaceutical company focused on the clinical and commercial development of its proprietary medicines for the treatment of various cancers. Its lead product candidate TG02, an oral multi-kinase inhibitor facilitates anti-tumor activ …
  • West Fraser Timber Co. Ltd. (WFT):企業の財務・戦略的SWOT分析
    West Fraser Timber Co. Ltd. (WFT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • General Mills Inc:戦略・SWOT・企業財務分析
    General Mills Inc - Strategy, SWOT and Corporate Finance Report Summary General Mills Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Sonoma Pharmaceuticals Inc (OCLS):企業の財務・戦略的SWOT分析
    Summary Sonoma Pharmaceuticals Inc (Sonoma), formerly Oculus Innovative Sciences, is a pharmaceutical company that develops, manufactures and markets prescription and non-prescription products for the treatment of dermatological conditions and advanced tissue care. The company offers products for ad …
  • Dairy Farmers of America Inc:戦略・SWOT・企業財務分析
    Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report Summary Dairy Farmers of America Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Samsung Securities Co Ltd (016360):企業の財務・戦略的SWOT分析
    Samsung Securities Co Ltd (016360) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Touchstone Exploration Inc (TXP):企業の財務・戦略的SWOT分析
    Summary Touchstone Exploration Inc (Touchstone), formerly Touchstone Resources Ltd is an upstream oil and gas exploration and production company that explores, produces, and develops, oil and gas properties in Trinidad and Tobago. The company holds interests, owns, and operates projects such as WD-4 …
  • Jelf Group PLC:企業のM&A・事業提携・投資動向
    Jelf Group PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Jelf Group PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestmen …
  • TTEC Holdings Inc.:企業の戦略・SWOT・財務情報
    TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report Summary TTEC Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Oando Plc (OANDO):石油・ガス:M&Aディール及び事業提携情報
    Summary Oando Plc (Oando) is a provider of integrated energy solutions to the oil and gas industry. Through its subsidiaries, the company explores for and produces oil and gas through the acquisition of rights in oil blocks on the Nigerian continental shelf and deep offshore. It has producing, devel …
  • Per Aarsleff Holding AS (PAAL B):企業の財務・戦略的SWOT分析
    Per Aarsleff Holding AS (PAAL B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆